Status:
UNKNOWN
Effectiveness of mRNA Covid-19 Vaccines on Cancer Patients:Observational Study. (ANTICOV)
Lead Sponsor:
Azienda Socio Sanitaria Territoriale di Cremona
Conditions:
Cancer
Covid-19
Eligibility:
All Genders
18+ years
Brief Summary
Based on recent data, COVID (COV) vaccination in cancer patients (pts) is strictly recommended. For oncologic pts,2 types of m-RNA vaccines have been approved: BNT162b2 (Pfizer, Biontech) and mRNA-127...
Detailed Description
Trial Design This is a monocentric observational study conducted by the Oncology Unit of Cremona (CR) Hospital, enrolling pts from Oncology, Hematology, Radiotherapy and Palliative Care of Cr Hospita...
Eligibility Criteria
Inclusion
- Cancer patients receiving active therapy (chemotherapy, immunotherapy, target therapy, radiotherapy)
- Cancer patients receiving hormonal therapy for metastatic disease.
- Must be ≥18 years of age.
- Written, signed consent for study participation.
Exclusion
- Cancer patients receiving hormonal therapy in adjuvant regimen.
- Patients in follow-up and who have completed their cancer treatment for \> 6 months.
- Life expectancy less than 3 months.
Key Trial Info
Start Date :
May 24 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04878796
Start Date
May 24 2021
End Date
May 1 2022
Last Update
July 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UO Oncologia, ASST di Cremona
Cremona, Lombardy, Italy, 26100